MCID: ACT010
MIFTS: 52

Acth-Secreting Pituitary Adenoma

Categories: Bone diseases, Cancer diseases, Endocrine diseases, Genetic diseases, Metabolic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Acth-Secreting Pituitary Adenoma

MalaCards integrated aliases for Acth-Secreting Pituitary Adenoma:

Name: Acth-Secreting Pituitary Adenoma 12 54 45 15 74
Cushing Disease 54 26
Pituitary-Dependant Hypercortisolism Disorder 26
Pituitary-Dependent Cushing's Disease 74
Pituitary Corticotroph Micro-Adenoma 54
Pituitary Dependent Cushing Syndrome 54
Pituitary-Dependent Cushing Syndrome 54
Pituitary-Dependant Cushing Syndrome 26
Pituitary-Dependant Hypercortisolism 26
Pituitary-Dependent Cushings Disease 56
Adenoma, Pituitary, Acth-Secreting 41
Pituitary Adenoma, Acth-Secreting 13
Acth-Producing Pituitary Adenoma 12
Corticotroph Pituitary Adenoma 54
Pituitary Acth Hypersecretion 26
Adrenal Gland Hyperfunction 74
Pituitary Cushing Syndrome 26
Corticotroph Adenoma 12
Cushing's Disease 54
Cushing Syndrome 74
Corticotropinoma 12
Hypercortisolism 26

Classifications:



External Ids:

Disease Ontology 12 DOID:7004
MeSH 45 D049913
NCIt 51 C7462
SNOMED-CT 69 21109002

Summaries for Acth-Secreting Pituitary Adenoma

NIH Rare Diseases : 54 ACTH-secreting pituitary adenoma is a condition characterized by elevated levels of a hormone called cortisol secreted by a tumor in the pituitary gland. It is part of a group of diseases that cause Cushing�??s syndrome, characterized by signs and symptoms that may include weight gain around the trunk and in the face, stretch marks, easy bruising, a hump on the upper back, muscle weakness, tiredness, thin bones that are prone to fracture (osteoporosis), mood disorders and memory problems, as well as an increased risk of infections, high blood pressure and diabetes. Women may have irregular menses and a lot of hair in the body (hirsutism). It  occurs when a benign pituitary tumor (adenoma) or pituitary hyperplasia causes the adrenal glands to produce large amounts of cortisol.  Some cases are caused by somatic mutations in the AIP and the GNAS genes. Rarely, an ACTH-secreting pituitary adenoma can be inherited, either as an isolated condition or as part of a genetic syndrome (such as multiple endocrine neoplasia type 1 (MEN1) and familial isolated pituitary adenoma), but most cases are sporadic. Treatment generally involves surgery to remove the tumor and medications to decrease cortisol levels.

MalaCards based summary : Acth-Secreting Pituitary Adenoma, also known as cushing disease, is related to pituitary-dependent cushing's disease and adenoma, and has symptoms including cushingoid facies An important gene associated with Acth-Secreting Pituitary Adenoma is POMC (Proopiomelanocortin), and among its related pathways/superpathways are Myometrial Relaxation and Contraction Pathways and Prolactin Signaling Pathway. The drugs Pasireotide and Somatostatin have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and adrenal gland, and related phenotypes are Increased cell death HMECs cells and endocrine/exocrine gland

Disease Ontology : 12 A functioning pituitary adenoma that characterized by excess cortisol a primary cause of Cushing's syndrome.

Wikipedia : 77 Cushing''s syndrome is a collection of signs and symptoms due to prolonged exposure to glucocorticoids... more...

Related Diseases for Acth-Secreting Pituitary Adenoma

Diseases in the Acth-Secreting Pituitary Adenoma family:

Pituitary Adenoma 4, Acth-Secreting

Diseases related to Acth-Secreting Pituitary Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 255)
# Related Disease Score Top Affiliating Genes
1 pituitary-dependent cushing's disease 32.2 CRH POMC PRL
2 adenoma 30.7 POMC PRL USP8
3 pituitary tumors 30.2 POMC PRL
4 gangliocytoma 30.2 CRH POMC
5 empty sella syndrome 30.1 POMC PRL
6 cortisone reductase deficiency 30.1 NR3C1 POMC
7 corticosteroid-binding globulin deficiency 30.0 NR3C1 POMC
8 hyperprolactinemia 30.0 POMC PRL
9 functioning pituitary adenoma 29.9 POMC PRL
10 adrenal adenoma 29.9 CRH POMC
11 endogenous depression 29.8 CRH NR3C1
12 withdrawal disorder 29.8 CRH POMC
13 hypokalemia 29.8 NR3C1 POMC
14 ectopic cushing syndrome 29.8 CRH POMC
15 conn's syndrome 29.8 CRH NR3C1 POMC PRL
16 pituitary apoplexy 29.8 POMC PRL
17 hyperandrogenism 29.8 POMC PRL
18 pituitary carcinoma 29.7 CRH POMC PRL
19 amenorrhea 29.7 CRH POMC PRL
20 hypoadrenalism 29.7 CRH POMC
21 adrenal cortical hypofunction 29.7 CRH POMC
22 hypopituitarism 29.6 CRH POMC PRL
23 diabetes insipidus 29.6 CRH POMC PRL
24 nelson syndrome 29.5 CRH NR3C1 POMC PRL
25 chromophobe adenoma 29.5 POMC PRL
26 fibromyalgia 29.5 CRH PRL
27 mood disorder 29.4 CRH NR3C1 POMC
28 anorexia nervosa 29.3 CRH POMC PRL
29 sheehan syndrome 29.2 CRH POMC PRL
30 major depressive disorder 28.9 CRH NR3C1 POMC PRL
31 pituitary adenoma 4, acth-secreting 11.6
32 mccune-albright syndrome 11.4
33 pituitary adenoma 1, multiple types 11.2
34 acth-independent macronodular adrenal hyperplasia 11.1
35 malignant acth producing neoplasm of pituitary gland 11.1
36 lipodystrophy, familial partial, type 2 11.0
37 familial partial lipodystrophy 11.0
38 primary pigmented nodular adrenocortical disease 11.0
39 pituitary adenoma 10.8
40 ovarian serous adenofibroma 10.2 NR3C1 POMC
41 acromegaly 10.2
42 hyperaldosteronism, familial, type i 10.2 NR3C1 POMC
43 allergic urticaria 10.2 CRH NR3C1
44 allergic encephalomyelitis 10.1 CRH POMC
45 acth deficiency, isolated 10.1 CRH POMC
46 fasting hypoglycemia 10.1 CRH POMC
47 osteoporosis 10.1
48 bone mineral density quantitative trait locus 8 10.1
49 bone mineral density quantitative trait locus 15 10.1
50 leukemia 10.1

Graphical network of the top 20 diseases related to Acth-Secreting Pituitary Adenoma:



Diseases related to Acth-Secreting Pituitary Adenoma

Symptoms & Phenotypes for Acth-Secreting Pituitary Adenoma

UMLS symptoms related to Acth-Secreting Pituitary Adenoma:


cushingoid facies

GenomeRNAi Phenotypes related to Acth-Secreting Pituitary Adenoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 8.92 IGFBP6 NR3C1 PRKCD USP8

MGI Mouse Phenotypes related to Acth-Secreting Pituitary Adenoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.35 CRH NR3C1 POMC PRKCD PRL
2 liver/biliary system MP:0005370 9.1 CRH NR3C1 POMC PRKCD PRL USP8

Drugs & Therapeutics for Acth-Secreting Pituitary Adenoma

Drugs for Acth-Secreting Pituitary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pasireotide Approved Phase 4,Phase 3,Phase 2 396091-73-9 9941444
2
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2 38916-34-6, 51110-01-1 53481605
3
Liraglutide Approved Phase 4 204656-20-2 44147092
4
Metformin Approved Phase 4,Phase 2,Phase 3 657-24-9 14219 4091
5
Zinc Approved, Investigational Phase 4 7440-66-6 32051
6
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-03-3
7
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-23-7 5754
8
Lactitol Investigational Phase 4 585-88-6, 585-86-4 493591
9 Hormones Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
11 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
12 insulin Phase 4
13 Insulin, Globin Zinc Phase 4
14 Hypoglycemic Agents Phase 4,Phase 2,Phase 3
15 Sitagliptin Phosphate Phase 4
16 Dipeptidyl-Peptidase IV Inhibitors Phase 4
17
protease inhibitors Phase 4
18 Incretins Phase 4
19 HIV Protease Inhibitors Phase 4
20 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 3,Phase 2,Not Applicable
21 Hydrocortisone hemisuccinate Phase 4,Phase 3,Phase 2,Not Applicable
22 Anti-Inflammatory Agents Phase 4,Phase 2
23 Hydrocortisone-17-butyrate Phase 4
24
Epinephrine Approved, Vet_approved Phase 3,Phase 2,Not Applicable 51-43-4 5816
25
Racepinephrine Approved Phase 3,Phase 2,Not Applicable 329-65-7 838
26
Dopamine Approved Phase 3,Phase 2 62-31-7, 51-61-6 681
27
Cabergoline Approved Phase 3,Phase 2 81409-90-7 54746
28
Mifepristone Approved, Investigational Phase 3,Phase 2,Not Applicable 84371-65-3 55245
29 Orange Approved Phase 3
30
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576
31
Octreotide Approved, Investigational Phase 3 83150-76-9 6400441 383414
32 glucocorticoids Phase 2, Phase 3,Phase 3,Not Applicable
33 Epinephryl borate Phase 3,Phase 2,Not Applicable
34 Pharmaceutical Solutions Phase 3
35 Adrenocorticotropic Hormone Phase 3,Phase 2,Early Phase 1
36 Melanocyte-Stimulating Hormones Phase 3,Phase 2
37 beta-endorphin Phase 3,Phase 2
38 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
39 Dopamine agonists Phase 3,Phase 2
40 Antiparkinson Agents Phase 3,Phase 2
41 Dopamine Agents Phase 3,Phase 2
42 Contraceptives, Postcoital Phase 3,Phase 2,Not Applicable
43 Contraceptives, Oral Phase 3,Phase 2,Not Applicable
44 Luteolytic Agents Phase 3,Phase 2,Not Applicable
45 Contraceptive Agents Phase 3,Phase 2,Not Applicable
46 Antineoplastic Agents, Hormonal Phase 3,Phase 2
47 Gastrointestinal Agents Phase 3,Phase 2
48 Radiopharmaceuticals Phase 3
49 Edotreotide Phase 3
50
Bexarotene Approved, Investigational Phase 1, Phase 2 153559-49-0 82146

Interventional clinical trials:

(show top 50) (show all 71)
# Name Status NCT ID Phase Drugs
1 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
2 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
3 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
4 Exploring the Effects of Corticosteroids on the Human Hippocampus Not yet recruiting NCT03896659 Phase 4 Hydrocortisone Oral;Placebo Oral Tablet
5 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
6 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
7 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
8 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
9 Prevention of Metabolic Complications of Glucocorticoid Excess Completed NCT01319994 Phase 2, Phase 3 Metformin;Placebo
10 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
11 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00936741 Phase 3 mifepristone
12 A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00569582 Phase 3 mifepristone
13 Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease Recruiting NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
14 Open-label Treatment in Cushing's Syndrome Recruiting NCT03621280 Phase 3 Levoketoconazole
15 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
16 A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome Recruiting NCT03697109 Phase 3 Relacorilant
17 Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Active, not recruiting NCT02180217 Phase 3 LCI699;LCI699 matching placebo
18 Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
19 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
20 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2 Gefitinib
21 Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment Unknown status NCT02713776 Phase 2 Pasireotide;Placebo
22 Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease Completed NCT00171951 Phase 2 Pasireotide
23 A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
24 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Completed NCT02468193 Phase 2 Osilodrostat
25 Study to Evaluate CORT125134 in Patients With Cushing's Syndrome Completed NCT02804750 Phase 2 CORT125134
26 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease Recruiting NCT03774446 Phase 2 Seliciclib
27 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition Recruiting NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
28 Extension Study to Evaluate the Safety and Clinical Benefit of Long-Term Use of Relacorilant in Patients With Cushing Syndrome Recruiting NCT03604198 Phase 2 relacorilant
29 Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer Recruiting NCT03157128 Phase 1, Phase 2 LOXO-292
30 Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Active, not recruiting NCT01915303 Phase 2 Pasireotide with or without cabergoline
31 Safety and Efficacy of LCI699 in Cushing's Disease Patients. Active, not recruiting NCT01331239 Phase 2 LCI699
32 Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors Active, not recruiting NCT02749227 Phase 2 Pasireotide LAR
33 Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Disease Not yet recruiting NCT03708900 Phase 2 LCI699
34 Treatment of Cushing's Disease With R-roscovitine Terminated NCT02160730 Phase 2 R-roscovitine
35 Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) Terminated NCT00612066 Phase 2 rosiglitazone maleate
36 Rosiglitazone in Treating Patients With Pituitary Tumors Terminated NCT00616642 Phase 2 rosiglitazone maleate
37 Pasireotide Therapy in Patients With Nelson's Syndrome Terminated NCT01617733 Phase 2 Pasireotide
38 Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion Terminated NCT00422201 Phase 2 Mifepristone
39 Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma Terminated NCT00813592 Phase 2 SOM230B
40 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
41 SOM230 Ectopic ACTH-producing Tumors Withdrawn NCT02780882 Phase 2 Pasireotide
42 Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease Unknown status NCT02603653 Not Applicable
43 Study of Depression, Peptides, and Steroids in Cushing's Syndrome Unknown status NCT00004334
44 Mutations of Glucocorticoid Receptor in Bilateral Adrenal Hyperplasia Unknown status NCT02810496 Not Applicable
45 Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools Unknown status NCT01775332 Not Applicable
46 Anesthesia Management of Retroperitoneal Adrenalectomies Unknown status NCT00894335
47 Cushing´s Disease Epidemiology in Sweden Completed NCT02350153
48 The Factors Associated With the Recurrence in Patients With Cushing Disease Completed NCT02233335
49 Cognition, Steroids, and Imaging in Cushings Disease Completed NCT00081341
50 Effects of Hormone Stimulation on Brain Scans for Cushing s Disease Completed NCT01459237 Early Phase 1 Acthrel

Search NIH Clinical Center for Acth-Secreting Pituitary Adenoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: acth-secreting pituitary adenoma

Genetic Tests for Acth-Secreting Pituitary Adenoma

Anatomical Context for Acth-Secreting Pituitary Adenoma

MalaCards organs/tissues related to Acth-Secreting Pituitary Adenoma:

42
Pituitary, Bone, Adrenal Gland, Skin, Thyroid, Liver, Brain

Publications for Acth-Secreting Pituitary Adenoma

Articles related to Acth-Secreting Pituitary Adenoma:

(show top 50) (show all 240)
# Title Authors Year
1
Outcomes after Gamma knife Stereotactic Radiosurgery in pediatric patients with Cushing's disease or Acromegaly: A multi-institutional study. ( 30790739 )
2019
2
Hypothalamic Vasopressin-Producing Tumors: Often Inappropriate Diuresis But Occasionally Cushing Disease. ( 30379651 )
2019
3
Tumor-Directed Therapeutic Targets in Cushing Disease. ( 30535260 )
2019
4
Plasma Agouti-Related Protein and Cortisol Levels in Cushing Disease: Evidence for the Regulation of Agouti-Related Protein by Glucocorticoids in Humans. ( 30597030 )
2019
5
Optical Imaging Technology: A Useful Tool to Identify Remission in Cushing Disease After Surgery. ( 30602178 )
2019
6
Recovery of Adrenal Function after Pituitary Surgery in Patients with Cushing Disease: Persistent Remission or Recurrence? ( 30636245 )
2019
7
Correction: Optical Imaging Technology: A Useful Tool to Identify Remission in Cushing Disease After Surgery. ( 30641579 )
2019
8
Overall and Disease-Specific Mortality in Patients With Cushing Disease: A Swedish Nationwide Study. ( 30715394 )
2019
9
Active Cushing Disease Is Characterized by Increased Adipose Tissue Macrophage Presence. ( 30722035 )
2019
10
Impact of USP8 gene mutations on protein deregulation in Cushing's disease. ( 30844069 )
2019
11
Surgical Outcomes and Comorbidities in Cushing Disease: 30 Years of Experience in a Referral Center. ( 31108069 )
2019
12
Endocrine Remission After Pituitary Stereotactic Radiosurgery: Differences in Rates of Response for Matched Cohorts of Cushing Disease and Acromegaly Patients. ( 29678528 )
2018
13
Consensus-driven in-hospital cortisol assessment after ACTH-secreting pituitary adenoma resection. ( 29143885 )
2018
14
Protein expression of somatostatin receptor 2, somatostatin receptor 5 and dopamine D2 receptor in normal pituitary gland and ACTH-secreting pituitary adenoma in dogs. ( 29864631 )
2018
15
Integration of Proteomics and Metabolomics Revealed Metabolite-Protein Networks in ACTH-Secreting Pituitary Adenoma. ( 30532734 )
2018
16
Severe Hypercortisolism with Hypokalemic Alkalosis Mimicking Ectopic Cushing Syndrome in a Patient with Cushing Disease Due to Pituitary Microadenoma. ( 30766837 )
2018
17
Management of Cerebral Venous and Sinus Thrombosis Following Transsphenoidal Surgery for Cushing Disease During Early Postoperative Period: Uncommon Neurosurgical Complication. ( 29499593 )
2018
18
Long-term outcomes of tissue-based ACTH-antibody assay-guided transsphenoidal resection of pituitary adenomas in Cushing disease. ( 29027854 )
2018
19
The Value of Perioperative Levels of ACTH, DHEA, and DHEA-S and Tumor Size in Predicting Recurrence of Cushing Disease. ( 29244084 )
2018
20
Variability of Late-Night Salivary Cortisol in Cushing Disease: A Prospective Study. ( 29329418 )
2018
21
CyberKnife Radiosurgery in the Multimodal Management of Patients with Cushing Disease. ( 29355797 )
2018
22
Technique of Whole-Sellar Stereotactic Radiosurgery for Cushing Disease: Results from a Multicenter, International Cohort Study. ( 29783006 )
2018
23
New Insights in Cushing Disease Treatment With Focus on a Derivative of Vitamin A. ( 29881371 )
2018
24
Children with MEN1 gene mutations may present first (and at a young age) with Cushing disease. ( 29927501 )
2018
25
Outcome of Transsphenoidal Surgery for Cushing Disease: A Single-Center Experience over 20 Years. ( 30031194 )
2018
26
PATHOGENESIS OF CUSHING DISEASE: AN UPDATE ON THE GENETICS OF CORTICOTROPINOMAS. ( 30084690 )
2018
27
Cell Cycle Regulators and Lineage-Specific Therapeutic Targets for Cushing Disease. ( 30147673 )
2018
28
Neurosurgical treatment of Cushing disease in pediatric patients: case series and review of literature. ( 30488233 )
2018
29
Bone morphogenetic protein 4 and bone morphogenetic protein receptor expression in the pituitary gland of adult dogs in healthy condition and with ACTH-secreting pituitary adenoma. ( 26542941 )
2017
30
Safety of transsphenoidal microsurgical approach in patients with an ACTH-secreting pituitary adenoma. ( 28005257 )
2017
31
Cryptococcal meningitis after transnasal transsphenoidal pituitary microsurgery of ACTH-secreting pituitary adenoma: A case report. ( 28700464 )
2017
32
A rare association: Cushing disease and central serous chorioretinopathy. ( 28457311 )
2017
33
Cushing Disease in a patient with Multiple Endocrine Neoplasia type 2B. ( 28435794 )
2017
34
A rare case of spontaneous Cushing disease remission induced by pituitary apoplexy. ( 28251551 )
2017
35
PRKAR1A mutation causing pituitary-dependent Cushing disease in a patient with Carney complex. ( 28522647 )
2017
36
Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors. ( 27448294 )
2017
37
Factors predicting the duration of adrenal insufficiency in patients successfully treated for Cushing disease and nonmalignant primary adrenal Cushing syndrome. ( 27395418 )
2017
38
Bilateral Testicular Tumors Resulting in Recurrent Cushing Disease After Bilateral Adrenalectomy. ( 27901643 )
2017
39
Endoscopic Endonasal Surgery for Remission of Cushing Disease Caused by Ectopic Intracavernous Macroadenoma: Case Report and Literature Review. ( 28003168 )
2017
40
Rapid Deterioration of Latent HBV Hepatitis during Cushing Disease and Posttraumatic Stress Disorder after Earthquake. ( 28183144 )
2017
41
Normalized Early Postoperative Cortisol and ACTH Values Predict Nonremission After Surgery for Cushing Disease. ( 28323961 )
2017
42
LONG-TERM OUTCOME OF THE DIFFERENT TREATMENT ALTERNATIVES FOR RECURRENT AND PERSISTENT CUSHING DISEASE. ( 28332874 )
2017
43
Diabetes in Cushing Disease. ( 28364356 )
2017
44
Pediatric Cushing disease: disparities in disease severity and outcomes in the Hispanic and African-American populations. ( 28422946 )
2017
45
Somatic USP8 Gene Mutations Are a Common Cause of Pediatric Cushing Disease. ( 28505279 )
2017
46
Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease. ( 28505327 )
2017
47
Recent advances in understanding Cushing disease: resistance to glucocorticoid negative feedback and somatic USP8 mutations. ( 28529722 )
2017
48
BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY. ( 28614003 )
2017
49
Outcomes of Primary Transsphenoidal Surgery in Cushing Disease: Experience of a Tertiary Center. ( 28711536 )
2017
50
Otolaryngic manifestations of Cushing disease. ( 28846797 )
2017

Variations for Acth-Secreting Pituitary Adenoma

Cosmic variations for Acth-Secreting Pituitary Adenoma:

9 (show top 50) (show all 51)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM1749198 USP8 pituitary,NS,adenoma,ACTH c.2159C>G p.P720R 15:50490450-50490450 0
2 COSM4997287 USP8 pituitary,NS,adenoma,ACTH c.2152T>C p.S718P 15:50490443-50490443 0
3 COSM416905 USP8 pituitary,NS,adenoma,ACTH c.2159C>A p.P720Q 15:50490450-50490450 0
4 COSM6995415 USP8 pituitary,NS,adenoma,ACTH c.2147C>A p.S716Y 15:50490438-50490438 0
5 COSM5967228 USP8 pituitary,NS,adenoma,ACTH c.2155T>C p.S719P 15:50490446-50490446 0
6 COSM3501986 USP8 pituitary,NS,adenoma,ACTH c.2147C>T p.S716F 15:50490438-50490438 0
7 COSM5967229 USP8 pituitary,NS,adenoma,ACTH c.2153C>T p.S718F 15:50490444-50490444 0
8 COSM10654 TP53 skin,face,other,hyperplasia c.637C>T p.R213* 17:7674894-7674894 0
9 COSM10995 TP53 skin,face,other,hyperplasia c.580C>T p.L194F 17:7674951-7674951 0
10 COSM43939 TP53 skin,face,other,hyperplasia c.632C>T p.T211I 17:7674899-7674899 0
11 COSM45444 TP53 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.587G>T p.R196L 17:7674944-7674944 0
12 COSM43555 TP53 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.736A>G p.M246V 17:7674227-7674227 0
13 COSM43931 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.523C>A p.R175S 17:7675089-7675089 0
14 COSM11286 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.1015G>T p.E339* 17:7670694-7670694 0
15 COSM10801 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.404G>A p.C135Y 17:7675208-7675208 0
16 COSM10659 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.817C>T p.R273C 17:7673803-7673803 0
17 COSM11071 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.1009C>T p.R337C 17:7670700-7670700 0
18 COSM44175 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.644G>C p.S215T 17:7674887-7674887 0
19 COSM5991542 STAG2 pituitary,NS,adenoma,ACTH c.1363G>C p.G455R 23:124057924-124057924 0
20 COSM326321 RB1 adrenal gland,adrenal gland,adrenal cortical carcinoma,cortisol producing c.1994T>G p.L665R 13:48459721-48459721 0
21 COSM225014 RB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.1960G>A p.V654M 13:48456349-48456349 0
22 COSM4167506 PRKACA adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.617T>G p.L206R 19:14097604-14097604 0
23 COSM28544 PIK3CA pituitary,NS,adenoma,ACTH c.3026G>A p.G1009E 3:179234183-179234183 0
24 COSM303944 PIK3CA pituitary,NS,adenoma,ACTH c.2984C>A p.A995D 3:179234141-179234141 0
25 COSM22589 MEN1 pituitary,NS,adenoma,ACTH c.1230C>A p.F410L 11:64805154-64805154 0
26 COSM4445248 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.1132G>T p.E378* 11:64805688-64805688 0
27 COSM4445249 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.808C>A p.L270M 11:64807195-64807195 0
28 COSM4445247 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.812G>C p.G271A 11:64807191-64807191 0
29 COSM4445246 MED12 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.4857G>T p.K1619N 23:71134842-71134842 0
30 COSM482 HRAS pituitary,NS,adenoma,ACTH c.34G>C p.G12R 11:534289-534289 0
31 COSM27887 GNAS pituitary,NS,adenoma,ACTH c.601C>T p.R201C 20:58909365-58909365 0
32 COSM27896 GNAS pituitary,NS,adenoma,ACTH c.680A>G p.Q227R 20:58909541-58909541 0
33 COSM27899 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.601C>A p.R201S 20:58909365-58909365 0
34 COSM27895 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.602G>A p.R201H 20:58909366-58909366 0
35 COSM4962873 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.679C>G p.Q227E 20:58909540-58909540 0
36 COSM5663 CTNNB1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.133T>C p.S45P 3:41224645-41224645 0
37 COSM5669 CTNNB1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.98C>T p.S33F 3:41224610-41224610 0
38 COSM5693 CTNNB1 adrenal gland,adrenal gland,adrenal cortical carcinoma,cortisol producing c.118A>G p.T40A 3:41224630-41224630 0
39 COSM5689 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.134C>G p.S45C 3:41224646-41224646 0
40 COSM5678 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.107A>C p.H36P 3:41224619-41224619 0
41 COSM5667 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.134C>T p.S45F 3:41224646-41224646 0
42 COSM5664 CTNNB1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.121A>G p.T41A 3:41224633-41224633 0
43 COSM5686 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.100G>A p.G34R 3:41224612-41224612 0
44 COSM5679 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.110C>G p.S37C 3:41224622-41224622 0
45 COSM5672 CTNNB1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.94G>A p.D32N 3:41224606-41224606 0
46 COSM17661 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.130C>G p.P44A 3:41224642-41224642 0
47 COSM5988492 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.101G>C p.G34A 3:41224613-41224613 0
48 COSM5681 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.95A>G p.D32G 3:41224607-41224607 0
49 COSM476 BRAF adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.1799T>A p.V600E 7:140753336-140753336 0
50 COSM5991541 BCOR pituitary,NS,adenoma,ACTH c.283G>A p.G95R 23:40075063-40075063 0

Expression for Acth-Secreting Pituitary Adenoma

Search GEO for disease gene expression data for Acth-Secreting Pituitary Adenoma.

Pathways for Acth-Secreting Pituitary Adenoma

Pathways related to Acth-Secreting Pituitary Adenoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.99 CRH IGFBP6 PRKCD
2
Show member pathways
11.88 NR3C1 PRKCD PRL
3 11.3 CRH POMC PRKCD
4 10.71 NR3C1 POMC PRL
5 9.8 CRH POMC

GO Terms for Acth-Secreting Pituitary Adenoma

Biological processes related to Acth-Secreting Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.55 CRH IGFBP6 NR3C1 POMC PRKCD
2 cellular response to dexamethasone stimulus GO:0071549 8.8 CRH NR3C1 USP8
3 parturition GO:0007567 8.65 CRH

Molecular functions related to Acth-Secreting Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.13 CRH IGFBP6 POMC
2 hormone activity GO:0005179 8.8 CRH POMC PRL

Sources for Acth-Secreting Pituitary Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....